News

FDA Approves Nucala for Chronic Obstructive Pulmonary Disease
By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
US Approves GSK Lung Disease Drug, Fueling Sanofi Rivalry
GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.
Medpage Today on MSN7h
FDA Approves Mepolizumab for COPD
Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
GSK's asthma drug wins FDA approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
Rethinking COPD diagnosis to improve accuracy and early detection
University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...
HealthDay on MSN1d
Persistent, New Mucus Plugs Associated With Faster Decline in FEV1 in COPD
For patients with chronic obstructive pulmonary disease (COPD), persistent and newly formed mucus plugs are associated with a ...
The American Journal of Managed Care3d
Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation
New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...
Pulmonology Advisor3d
Women and Lung Disease: Sex-Specific Patterns in COPD, Asthma, and OSA
Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...
PharmExec10h
FDA Approves GSK’s Nucala for Chronic Obstructive Pulmonary Disease
Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.